Verastem (VSTM) Amortization - Intangibles (2018 - 2026)

Verastem (VSTM) posted quarterly Amortization - Intangibles of $279000.0 for Q1 2026, down 6.38% quarter-over-quarter from $298000.0 in Q4 2025.

Analysis

Verastem (VSTM) Amortization - Intangibles (2018 - 2026) Analysis & Trends

Verastem's Amortization - Intangibles history runs 5 years deep, the most recent figure standing at $279000.0 for Q1 2026.

In Q1 2026, Amortization - Intangibles changed N/A year-over-year to $279000.0; the TTM figure through Mar 2026 stood at $995000.0 (changed N/A YoY), while the FY2025 annual figure was $698000.0, changed N/A from the prior year.
Amortization - Intangibles for Q1 2026 stood at $279000.0, down from $298000.0 in the prior quarter.
The five-year high for Amortization - Intangibles was $298000.0 in Q4 2025, with the low at $128000.0 in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.77 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.51 Bn	77.52 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.20 Bn	53.06 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	39.99 Bn	34.89 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.40 Bn	27.56 Bn	-
9	Insmed	27.44 Bn	26.28 Bn	358.27 Mn
10	Verastem	800.93 Mn	664.58 Mn	36.32 Mn

Historic Data

Download Data